Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Sidoti & Co. Upgrades Staar Surgical to Buy

Sidoti & Co. analyst James Sidoti upgrades Staar Surgical (NASDAQ:STAA) from Neutral to Buy.

byBenzinga Newsdesk

November 7, 2022

1 minute read

Sidoti & Co. analyst James Sidoti upgrades Staar Surgical (NASDAQ:STAA) from Neutral to Buy.

BridgeBio Partnered Protein Replacement Therapy Shows Promising Action In Painful Skin Blistering Disorder

By Vandana Singh

May 20, 3:04 PM

BridgeBio Pharma Inc (NASDAQ:BBIO) and affiliate company Phoenix Tissue Repair announced data from the Phase 2 trial of PTR-01 in recessive…

BBIO

News

Remark Holdings Successfully Achieves Compliance with Nasdaq Listing Requirements

By Benzinga Newsdesk

January 12, 10:01 AM

Remark Holdings, Inc. (NASDAQ:MARK), a diversified global technology company with leading artificial intelligence powered computer vision solutions, today announced that it received a letter from The Nasdaq Stock Market

MARK

Analyst Ratings

11 Analysts Have This to Say About AvalonBay Communities

By Benzinga Insights

November 7, 10:04 AM

Within the last quarter, AvalonBay Communities (NYSE:AVB) has observed the following analyst ratings:

AVB

FDA
News

Bicycle Therapeutics Announces Publication Of Article Highlighting Preclinical Data From BT7480 Program In Journal For ImmunoTherapy Of Cancer

By Benzinga Newsdesk

November 2, 7:19 AM

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that an

BCYC

Sidoti & Co. Upgrades Staar Surgical to Buy

Related Posts

BridgeBio Partnered Protein Replacement Therapy Shows Promising Action In Painful Skin Blistering Disorder

Remark Holdings Successfully Achieves Compliance with Nasdaq Listing Requirements

11 Analysts Have This to Say About AvalonBay Communities

Bicycle Therapeutics Announces Publication Of Article Highlighting Preclinical Data From BT7480 Program In Journal For ImmunoTherapy Of Cancer